CalciMedica
Stock Forecast, Prediction & Price Target
CalciMedica Financial Estimates
CalciMedica Revenue Estimates
CalciMedica EBITDA Estimates
CalciMedica Earnings per Share Estimates
Passed | Analyst forecast | ||||||
---|---|---|---|---|---|---|---|
Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | ||
Revenue
% change YoY
| $0 N/A | $0 0% | $0 0% | Avg: $12.5M Low: $12.5M High: $12.5M avg. 0% | Avg: $2.8M Low: $2.8M High: $2.8M avg. -77.60% | ||
Net Income
% change YoY
| $-35.82M N/A | $-35.60M 0.60% | $-34.35M 3.50% | Avg: $-27.86M Low: $-8.12M High: $-7.22M avg. 18.89% | Avg: $-32.45M Low: $-8.89M High: $-6.15M avg. -16.44% | ||
EBITDA
% change YoY
| $-35.94M N/A | $-29.91M 16.77% | $-34.18M -14.28% | Avg: $0 Low: $0 High: $0 avg. 100% | Avg: $0 Low: $0 High: $0 avg. 0% | ||
EPS
% change YoY
| -$23.66 N/A | -$23.2 1.94% | -$7.65 67.02% | Avg: -$1.71 Low: -$1.81 High: -$1.61 avg. 77.64% | Avg: -$1.68 Low: -$1.98 High: -$1.37 avg. 2.04% | ||
Operating Expenses
% change YoY
| $35.94M N/A | $33.21M -7.59% | $21.81M -34.31% | Avg: $0 Low: $0 High: $0 avg. -100% | Avg: $0 Low: $0 High: $0 avg. 0% |
FAQ
What is CalciMedica stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 1.22% in 2025-2026.
We have gathered data from 2 analysts. Their low estimate is -8.12M, average is -27.86M and high is -7.22M.
What is CalciMedica stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of -38.80% in 2025-2026.
We have gathered data from 3 analysts. Their low revenue estimate is $12.5M, average is $12.5M and high is $12.5M.
What is CalciMedica stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 39.84% in 2025-2026.
We have gathered data from 2 analysts. Their low earnings per share estimate is -$1.81, average is -$1.71 and high is $-1.61.
What is the best performing analyst?
In the last twelve months analysts have been covering CalciMedica stock. The most successful analyst is Leland Gershall.